- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02201771
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery (DACAB)
Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
The study population will include all patients undergoing elective CABG. Consent and randomization will occur before surgery. Total 500 patients undergoing elective CABG will be randomly assigned into three groups with 1:1:1 ratio(167 patients per group) in this open-label study. All the enrolled patients will stop oral antiplatelet drugs according to local protocol before the surgery. Within the first 24 hours after surgery, study medication should be restarted and continued for 12 months. Arm A will restart oral antiplatelet drugs by giving aspirin 100mg qd, Arm B will also restart oral antiplatelet drugs by giving ticagrelor 90mg bid plus aspirin 100mg qd and Arm C will also restart oral antiplatelet drugs by giving ticagrelor 90mg bid. Treatment will continue for 12 months, at which time patients will undergo a multislice computed tomography angiography to assess vein graft patency.
This study is designed to show the superiority of ticagrelor and ticagrelor plus aspirin as compared with aspirin monotherapy respectively for the 1-year primary efficacy end point of vein graft patency.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study is designed to show the superiority of ticagrelor and ticagrelor plus aspirin as compared with aspirin monotherapy respectively for the 1-year primary efficacy end point of vein graft patency. The primary comparison includes two separate parts. One is to demonstrate T+A better than A and the other is T better than A.
One year rate of vein graft patency in the aspirin group is estimated as 80%. The assumed rate of ticagrelor plus aspirin is 90%. With a two-sided alpha level 0.05 and 80% power, 199 grafts to each group are required. On the other hand, if we assume the rate of ticagrelor monotherapy has the 1-year vein graft patency rate of 87%, under the same two-sided 0.05 alpha 441 grafts in each arm will offer 80% power to show the superiority of ticagrelor along for the primary efficacy end point.
Combined the above two assumptions, if the allocation rate is 1:1:1, this study needs to recruit 1,323 grafts in total (441 in each) to achieve the pre-specified power for both the two comparisons (T+A vs. A and T vs. A).
The principle investigator assumes that the average number of the vien grafts in one patient is 2.7-3.0. With this assumption, 500 patients are to be recruited, which will provide us a total of 1350 - 1500 grafts.
According to the above, this study will be a confirmatory clinical trial to the primary endpoint.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
Henan
-
Zhengzhou, Henan, Cina
- Henan Provincial People's Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina
- Jiangsu Province Hospital
-
Nanjing, Jiangsu, Cina
- Nan Jing First Hospital
-
-
Shanghai
-
Shanghai, Shanghai, Cina, 200433
- Changhai Hospital of Shanghai
-
Shanghai, Shanghai, Cina, 200025
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Shanghai, Shanghai, Cina, 200092
- Xinhua Hospital, Shanghai Jiaotong University School of Medicine
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients able to provide written informed consent
- Provision of informed consent prior to any study specific procedures
- Female and male patients aged 18-80 years
- Indication for CABG surgery
Exclusion Criteria:
- Cardiogenic shock, haemodynamic instability
- Need for urgent revascularization within 5 days from presentation
- Single vessel disease
- Two vessel disease with normal left ventricular function (> 50%)
- Need for concomitant other cardiac surgery (e.g. valve replacement)
- Need for dual antiplatelet treatment for the patients undergoing CABG after acute coronary syndrome(ACS)
- Contraindication for aspirin and ticagrelor use(e.g. known allergy)
- History of bleeding diathesis within 3 months prior presentation
- History of significant GI bleed within 1 year prior presentation
- History of peptic ulcer without GI bleeding in past 3 years
- History of intracranial hemorrhage
- History of moderate to severe liver impairment
- Patient requires dialysis
- Patient with an increased risk of bradycardic events (as patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree arteriolar-venular block or bradycardic-related syncope)
- Need vitamin K antagonist therapy after bypass surgery eg. persistent atrial fibrillation, mechanical valves
- Known, clinically important thrombocytopenia(i.e. < 100*109/L)
- Known, clinically important anaemia (i.e. <100g/L)
- Participation in another investigational drug or device study in the last 30 days
- Pregnancy or lactation(for premenopausal women 2 methods of reliable contraception, one of which must barrier method, are required)
- Concomitant oral or intravenous therapy with strong cytochrome P450 3A4(CYP3A4) inhibitors, CYP3A4 substrates with narrow therapeutic indices, or strong CYP3A4 inducers which cannot be stopped for the course of the study (strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, over 1 litre daily of grapefruit juice. Substrates with narrow therapeutic index: cyclosporine, quinidine. Strong inducers: rifampin, phenytoin, carbamazepine. )
- Any other condition such as active cancer
- Life expectancy less than 12 months that may result in protocol non-compliance or a risk for being lost to follow up
- Indication for major surgery(e.g. cancer treatment, carotid surgery, cerebral surgery, major vascular surgery)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Aspirin
aspirin 100mg tablet by mouth daily for 12 months
|
|
Sperimentale: Ticagrelor plus Aspirin
ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
|
|
Sperimentale: Ticagrelor
ticagrelor 90mg tablet by mouth twice daily for 12 months
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The Patency of Saphenous Vein Grafts
Lasso di tempo: up to 12 months
|
assessed by multislice computed tomography angiography (MSCTA) or coronary angiography(CAG).
FitzGibbon grade A (stenosis <50%) is defined as "patency".
|
up to 12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The Patency of Saphenous Vein Grafts
Lasso di tempo: up to 7 days
|
assessed by MSCTA or CAG.
FitzGibbon grade A (stenosis <50%) is defined as "patency".
|
up to 7 days
|
The Rate of Post-operative Atrial Fibrillation After CABG.
Lasso di tempo: up to 7 days
|
Number of Participants with Post-operative Atrial Fibrillation after CABG
|
up to 7 days
|
The Rate of Freedom From Angina According to Canadian Cardiovascular Society (CCS) Classification
Lasso di tempo: up to 12 months
|
Number of Participants Free of Angina per CCS Classification
|
up to 12 months
|
The Number of Major Adverse Cardiovascular Event (MACE)
Lasso di tempo: up to 12 months
|
MACE, composite of CV death, myocardial infarction or stroke (ischaemic or unknown etiology)
|
up to 12 months
|
Number of the Major Bleeding Events
Lasso di tempo: up to 12 months
|
According to modified TIMI criteria, the "Major Bleeding Events" is defined as the combination of CABG-related bleeding and non-CABG-related major bleeding(Intracranial bleeding, Clinically overt signs of hemorrhage with hemoglobin drop ≥5 g/dL and Fatal bleeding).
|
up to 12 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The Rate of Gastroduodenal Injury Assessed by Esophagogastroduodenoscopy (EGD)
Lasso di tempo: at 12 months
|
Not all but the patients recruited in Ruijin Hospital
|
at 12 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Qiang Zhao, MD.PhD, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Direttore dello studio: Yunpeng Zhu, MD., Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Effetti fisiologici delle droghe
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Agenti del sistema nervoso periferico
- Inibitori enzimatici
- Analgesici
- Agenti del sistema sensoriale
- Agenti antinfiammatori, non steroidei
- Analgesici, non narcotici
- Agenti antinfiammatori
- Agenti antireumatici
- Agenti fibrinolitici
- Agenti modulanti la fibrina
- Inibitori dell'aggregazione piastrinica
- Inibitori della ciclossigenasi
- Antipiretici
- Antagonisti del recettore purinergico P2Y
- Antagonisti del recettore purinergico P2
- Antagonisti purinergici
- Agenti purinergici
- Aspirina
- Ticagrelor
Altri numeri di identificazione dello studio
- ISSBRIL0211
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Bypass coronarico
-
Nanjing First Hospital, Nanjing Medical UniversityCompletatoBypass cardiopolmonare | Bypass con innesto dell'arteria coronariaCina
-
Università Vita-Salute San RaffaeleCompletatoChirurgia cardiaca | Bypass con innesto dell'arteria coronaria | Bypass aortocoronaricoCroazia, Italia, Cina, Malaysia, Federazione Russa, Portogallo, Bahrein, Brasile, Bulgaria, Cechia, Egitto, Arabia Saudita, Serbia
-
Mayo ClinicCompletatoBypass gastrico Roux-en-Y | Bypass gastrico | Chirurgia bariatricaStati Uniti
-
Baxter Healthcare CorporationCompletatoBypass cardiopolmonare | Sternotomia | Chirurgia cardiaca che richiede bypass cardiopolmonare e sternotomia medianaStati Uniti
-
Kartal Kosuyolu Yuksek Ihtisas Education and Research...Trakya University Faculty of Medicine HospitalCompletatoChirurgia cardiaca | Desflurano | Bypass cardiopolmonare | Chirurgia dell'innesto di bypass dell'arteria coronaria | Peptide natriuretico cerebrale | Risultato
-
The Medicines CompanyCompletatoBypass cardiopolmonare | Innesto di bypass dell'arteria coronaria
-
Yale UniversityGlenn Memorial FundReclutamento
-
University Hospital, GhentCompletato
-
Assistance Publique - Hôpitaux de ParisGFICompletatoBypass coronaricoFrancia
-
Aristotle University Of ThessalonikiCompletatoBypass cardiopolmonareGrecia
Prove cliniche su Ticagrelor
-
Federico II UniversityAdvicePharma GroupCompletatoInfarto miocardico | Disfunsione dell'arteria coronaria | Sindrome coronarica acuta | STEMI | NSTEMIItalia
-
University of FloridaCompletato
-
AstraZenecaParexelCompletato
-
Collegium Medicum w BydgoszczyCompletato
-
AstraZenecaCompletatoInfarto miocardico | Ictus | Aterotrombosi | Morte cardiovascolareSvezia, Stati Uniti, Australia, Brasile, Bulgaria, Repubblica Ceca, Francia, Italia, Corea, Repubblica di, Perù, Polonia, Federazione Russa, Sud Africa, Spagna, Tacchino, Regno Unito, Germania, Filippine, Cina, Ungheria, R... e altro ancora
-
University of FloridaAstraZenecaCompletatoDisfunsione dell'arteria coronariaStati Uniti
-
University of FloridaThe Medicines CompanyCompletatoDisfunsione dell'arteria coronariaStati Uniti
-
Weill Medical College of Cornell UniversityCanadian Institutes of Health Research (CIHR)Non ancora reclutamentoMalattia coronarica cronicaStati Uniti, Austria, Canada, Germania, Svezia
-
Centro Hospitalario La ConcepcionReclutamento
-
University of KarachiPharmEvo Private Limited., PakistanCompletato